Bright Minds Biosciences DRUG.CN · CAD
Health Care · Canadian Securities Exchange · 🇨🇦 Canada
26.00
-0.42%
Close of 5 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bright Minds Biosciences
Its shares trade on Canadian Securities Exchange under the ticker DRUG.CN. It has been listed since 8 February 2021.
Bright Minds Biosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-02-08. Bright Minds Biosciences Inc. is a biotechnology company. The firm is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy and pain. The firm has a portfolio of serotonin agonists designed to target neurocircuit abnormalities to treat disorders, such as resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. The company is focused on developing a line of serotonergic 5-Hydroxytryptamine (5-HT) drug candidates that target the 5-HT2C, 5-HT2A and 5-HT2A + 5-HT2C receptors. Its offers 5-HT2C for the treatment of dravet syndrome and behavioral disorders. Its offers 5-HT2A for treatment of depression and other neuropsychiatric disorders. The firm offers 5-HT2A + 5-HT2C for several chronic pain disorders/neuropathic pain syndromes, including cluster headaches and chemotherapy-induced peripheral neuropathy.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Feb 2021
- Website
- brightmindsbio.com ↗
Leadership
Pay as last reported
- Mr. Ian McdonaldPresident, Chief Executive Officer, Director, since 2019C$213,239
- Mr. Ryan CheungChief Financial OfficerC$120,000
- Dr. Jan PedersenChief Scientific Officer, Director, since 2022C$448,583
- Dr. Stephen CollinsChief Medical Officer
- Mr. Nils BottlerIndependent DirectorC$17,891
- Mr. Jeremy FryzukIndependent DirectorC$17,891
- Dr. David WeinerIndependent DirectorC$39,488
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bright Minds Biosciences Inc focuses on neuropsychiatric disorders and epilepsy treatments with serotonin agonists.
- The company's portfolio includes 5-HT2C for dravet syndrome and behavioral disorders.
- Bright Minds Biosciences Inc develops 5-HT2A and 5-HT2A + 5-HT2C for depression and chronic pain.
Weaknesses
- The company has no products approved for market yet.
- Bright Minds Biosciences Inc has no revenue from commercial sales.
- The firm's focus on serotonin agonists limits its market diversification.
Opportunities
- Bright Minds Biosciences Inc can expand into the US market for neuropsychiatric treatments.
- The company may benefit from growing demand for treatments for PTSD and chronic pain.
- Bright Minds Biosciences Inc could partner with pharmaceutical companies for drug development.
Threats
- The biotechnology industry faces high R&D costs and regulatory hurdles.
- Bright Minds Biosciences Inc competes with established pharmaceutical firms.
- The company's reliance on serotonin agonists could be challenged by new therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.